SPEAKER: Hongyue
Dai, Rosetta Inpharmatics
TITLE: Gene Expression Profiling Predicts
Clinical Outcome of Breast Cancer
ABSTRACT:
Breast cancer patients with the same stage of
disease can have markedly
different treatment responses and overall outcome. The strongest predictors
for metastases, e.g., lymph node status and histological grade, fail to
accurately classify breast tumors according to their clinical behavior.
Chemo- or hormonal therapy reduces the risk of distant metastases by
approximately 1/3rd, although 70-80% of the patients would have survived
without this treatment. We used DNA microarray analysis on primary breast
tumors of 78 young patients and applied supervised classification to
identify a gene expression signature strongly predictive of a short
interval to distant metastases in lymph node negative patients. A cohort of
295 samples verified the predictive power of those 70 genes. In addition, a
signature was established that identifies tumors of BRCA1 carriers. This
gene expression profile outperforms all currently used clinical parameters
in pre
COFFEE: 3:45 p.m., 104 Snedecor Hall